Interact with experts and peers.

Recent Posts

5 of 5 Shown
  • How Does the AASLD/IDSA HCV Guidance Weigh in on Management of HIV Coinfection?

    Douglas T. Dieterich MD - 10/9/2014
    There is great interest in offering coinfected patients the same opportunity for cure as monoinfected patients. The AASLD/IDSA guidance has developed recommendations aimed at maximizing cure in different populations of coinfected individuals.
  • My Take on the Guidance From AASLD/IDSA for Treating Interferon-Ineligible Patients With Genotype 1 HCV Infection

    Paul Y. Kwo MD - 10/9/2014 1 comment / Last Comment: 10/16/2014
    Historically, evaluating patients for interferon eligibility was critical. Today, interferon-free regimens are evolving and soon they will be standard practice for even the most difficult-to-treat disease.
  • Delivering on the Promise: Maximizing SVR in the Real World

    Jordan J. Feld MD, MPH - 10/6/2014 3 comments / Last Comment: 10/13/2014
    Delivering the successes of recent HCV therapy trials to the real world will take some work, but here is how it can be achieved.
  • Prioritizing Patients for HCV Therapy: The Case for Treating Before Advanced Disease

    Nancy Reau MD - 9/23/2014 3 comments / Last Comment: 10/4/2014
    Despite remarkable advances in curative treatments for HCV, many patients are being denied insurance coverage, as priority access to these costly medications is given to those with advanced disease.
  • Are New HCV Therapies Ready for Use in Transplant Patients?

    Paul Y. Kwo MD - 7/10/2014 4 comments / Last Comment: 9/18/2014
    Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
5 of 5 Shown
Show 0 More